Comparison Between Antidiabetic Weight Loss Medication

@article{1708487,
      author = { Khashayar Mohammadi},
      title = {Comparison Between Antidiabetic Weight Loss Medication},
      journal = {Iconic Research And Engineering Journals},
      year = {2025},
      volume = {8},
      number = {11},
      pages = {1422-1432},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1708487.pdf},
      abstract = {The increasing global prevalence of type 2 diabetes mellitus (T2DM) and obesity requires therapeutic strategies that can ensure both glycemic control and weight management. The purpose of this review article is a comparative study of the agents used in the treatment of T2DM that can cause intentional weight loss, with the main focus on GLP-1 RAs, SGLT2is, and newer combination therapies: the efficacy, safety, mechanisms of action, and long-term metabolic alternatives afforded by these drugs. Available clinical trial and real-world evidence suggests that GLP-1 RA can have a more profound weight loss effect accompanied by glycemic improvement, most prominently with semaglutide and liraglutide. Conversely, SGLT2is bring modest weight loss and concomitant cardiovascular and renal benefits. In contrast, the role of emerging dual agonists and combination therapies is examined for optimizing treatment outcomes for their metabolo-centric therapy. The intent of this comparison is to help clinicians in the individualized management of patients by aligning choice of therapy according to metabolic targets and comorbidity profiles.},
      keywords = {type 2 diabetes, weight loss, anti-diabetic drugs, body composition, diabesity},
      month = {May},
  }